STOCK TITAN

Avinger, Inc. - AVGR STOCK NEWS

Welcome to our dedicated page for Avinger news (Ticker: AVGR), a resource for investors and traders seeking the latest updates and insights on Avinger stock.

Avinger, Inc. (NASDAQ: AVGR) is a commercial-stage medical device company committed to transforming the treatment of Peripheral Artery Disease (PAD) through innovative, image-guided, catheter-based systems. Founded and headquartered in Redwood City, California, Avinger designs, manufactures, and sells its proprietary Lumivascular platform, which includes the Lightbox imaging console, the Ocelot family of catheters for penetrating chronic total occlusions (CTOs), and the Pantheris family of atherectomy devices for removing arterial plaque.

Avinger's mission is to significantly improve clinical outcomes for PAD patients by offering precision and real-time imaging that enhances both diagnosis and treatment. The company's groundbreaking products are developed to address the needs of over 200 million PAD patients worldwide.

Key highlights of Avinger's product lineup include:

  • Lightbox Imaging Console: An advanced system providing real-time intravascular imaging.
  • Ocelot Catheters: Designed for crossing chronic total occlusions with precision.
  • Pantheris Atherectomy Devices: The first-ever image-guided devices for the removal of arterial plaque.
  • Tigereye ST CTO-Crossing Catheter: Launched to significant market enthusiasm, providing enhanced performance for complex procedures.

Recent financial disclosures indicate that Avinger is actively expanding its commercial footprint. The company recently reported financial results for the third quarter of 2023, with total revenue of $1.8 million and notable developments including the launch of the Tigereye ST and Pantheris LV systems. Despite a net loss of $4.5 million, Avinger continues to invest in product development and sales expansion, primarily in the United States.

A key strategic move for Avinger has been the newly formed partnership with Zylox-Tonbridge, a leading Chinese medical device company. This collaboration is set to provide up to $15 million in equity funding and facilitate Avinger's entry into the Greater China market. The partnership also aims to enhance manufacturing efficiency and explore new revenue opportunities through product distribution in the U.S. and Germany.

In addition to advancing its peripheral products, Avinger is making strides in the coronary space. The company is developing a new image-guided system for treating coronary artery disease (CAD), with plans to file an Investigational Device Exemption (IDE) application with the FDA by mid-2024. This development emphasizes Avinger's commitment to addressing unmet medical needs across both peripheral and coronary segments.

For the most current updates and detailed information on Avinger, Inc., their products, financial reports, and more, please visit their official website at www.avinger.com.

Rhea-AI Summary

Avinger (Nasdaq: AVGR), a medical device company, announced that CFO Mark Weinswig will attend the Q1 Virtual Investor Summit from March 23-25, 2021. Weinswig will present on March 23rd at 4:40 PM ET and will be available for one-on-one meetings. The summit features over 100 companies and 300 investors, focusing on small and micro-cap companies. Avinger specializes in treating Peripheral Artery Disease (PAD), which affects over 12 million people in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.32%
Tags
conferences
-
Rhea-AI Summary

Avinger, Inc. (NASDAQ:AVGR) will release its financial results for Q4 and full year 2020 after market close on March 11, 2021. The company offers the first intravascular image-guided catheter-based system for diagnosing and treating Peripheral Artery Disease (PAD), which affects over 12 million people in the U.S. A conference call will follow at 1:30 PM PT/4:30 PM ET, with details available on the company’s website. A replay will be accessible post-call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
none
-
Rhea-AI Summary

Avinger Inc. (AVGR) announced an underwriting agreement with Aegis Capital Corp. to sell 10 million shares of common stock at a public price of $1.44 per share, representing a 10% discount from the January 28, 2021 closing price. The offering aims to raise capital for working and corporate expenses, including R&D, regulatory submissions, and potential acquisitions. The anticipated closing date is around February 2, 2021. The shares are being offered under the company's shelf registration statement with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.32%
Tags
Rhea-AI Summary

Avinger, Inc. (NASDAQ:AVGR) announced it has regained compliance with Nasdaq listing requirements as of January 26, 2021. This compliance relates to the minimum bid price rule necessary for continued listing on the Nasdaq Capital Market. Avinger specializes in innovative medical devices for the diagnosis and treatment of Peripheral Artery Disease (PAD), a condition affecting over 12 million people in the U.S. and more than 200 million globally. The company's Lumivascular platform includes advanced imaging and catheter technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.04%
Tags
none
-
Rhea-AI Summary

Avinger, Inc. (NASDAQ:AVGR) announced a loan amendment with CRG Partners III L.P. on January 22, 2021, enhancing liquidity by approximately $14.2 million through extending the interest-only period and maturity date of its term loan. The interest-only period now extends to December 31, 2023, while the maturity date has been pushed to December 31, 2025. This change allows Avinger to defer payments, improve financial stability, and focus on revenue growth and device launches, according to CEO Jeff Soinski.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.02%
Tags
none
-
Rhea-AI Summary

Avinger, Inc. (AVGR) announced significant growth in its intellectual property portfolio with the issuance of 19 new patents in 2020, including 10 in the U.S. and 9 internationally. This expansion reinforces Avinger's leadership in the treatment of Peripheral Artery Disease (PAD) with its unique intravascular imaging technology. The company's patent portfolio now totals 179, enhancing its competitive edge in the market. Looking ahead, Avinger plans to advance its next-generation imaging console, Lightbox 3, through regulatory processes, revealing potential revenue growth opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.33%
Tags
none
Rhea-AI Summary

Avinger, Inc. (NASDAQ:AVGR) announced the full commercial launch of its Tigereye™ image-guided chronic total occlusion (CTO) crossing system on January 15, 2021. Following a limited launch in Q4 2020, where approximately 50 successful CTO cases were performed at 12 clinical sites in the U.S. and Germany, the Tigereye device is now available for order in these markets. The device features high-definition intravascular imaging and capabilities designed to enhance treatment efficiency for complex PAD cases. Avinger aims for increased revenue growth opportunities in 2021 through its advanced product offerings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.43%
Tags
none
-
Rhea-AI Summary

Avinger, Inc. (NASDAQ:AVGR) will participate in the H.C. Wainwright Bioconnect 2021 Conference from January 11-14, 2021. The company will present a pre-recorded session available on-demand starting January 11. Additionally, Avinger executives will host one-on-one meetings with institutional investors during the conference dates. The company, which focuses on image-guided systems for diagnosing and treating Peripheral Artery Disease (PAD), aims to transform vascular disease treatment through its innovative products, including the Lumivascular platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.04%
Tags
conferences
-
News
Rhea-AI Summary

Avinger, Inc. (Nasdaq:AVGR) announced results from its Annual Meeting held on December 23, 2020. Key proposals included electing a director, ratifying the public accountant, and a reverse stock split. While the majority voted in favor of the reverse split, it failed to achieve the necessary majority of outstanding shares. CEO Jeff Soinski emphasized plans for 2021, including the commercial launch of the Tigereye CTO device and advancements in the Lightbox 3 imaging console. Avinger remains well-capitalized for its growth strategy despite the reverse split setback.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.73%
Tags
none
Rhea-AI Summary

Avinger, Inc. (AVGR) has adjourned its annual stockholder meeting to December 23, 2020, to continue soliciting votes for Proposal 3, a reverse stock split. A quorum was present, but only 60% of votes cast supported the proposal, falling short of the majority needed. Approval is crucial to maintain Nasdaq listing compliance. CEO Jeff Soinski emphasized the need for immediate votes to avoid additional costs. Institutional advisors ISS and Glass Lewis endorse the proposal, viewing it as vital for Avinger's future. The company has a solid financial position to support growth plans for 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
none

FAQ

What is the current stock price of Avinger (AVGR)?

The current stock price of Avinger (AVGR) is $0.4826 as of December 20, 2024.

What is the market cap of Avinger (AVGR)?

The market cap of Avinger (AVGR) is approximately 2.3M.

What does Avinger, Inc. do?

Avinger, Inc. designs, manufactures, and sells image-guided, catheter-based systems for the treatment of Peripheral Artery Disease (PAD).

What are Avinger's main products?

Avinger's main products are the Lightbox imaging console, Ocelot catheters for CTOs, and Pantheris atherectomy devices.

Where is Avinger, Inc. based?

Avinger, Inc. is based in Redwood City, California, USA.

How is Avinger expanding its market presence?

Avinger is expanding through new product launches, increasing its sales team, and forming strategic partnerships, such as with Zylox-Tonbridge in China.

What recent financial results has Avinger reported?

For the third quarter of 2023, Avinger reported a revenue of $1.8 million and a net loss of $4.5 million.

What is the significance of Avinger's partnership with Zylox-Tonbridge?

The partnership with Zylox-Tonbridge will provide up to $15 million in equity funding, help Avinger enter the Greater China market, and improve manufacturing efficiency.

Is Avinger developing any new products?

Yes, Avinger is developing a new image-guided system for coronary artery disease (CAD) and plans to file an IDE application with the FDA by mid-2024.

What is Avinger's mission?

Avinger's mission is to radically change the treatment of vascular disease through its innovative Lumivascular platform.

How can I get more information about Avinger, Inc.?

For more information, you can visit Avinger's official website at www.avinger.com.

What are Avinger's latest product launches?

Avinger has recently launched the Tigereye ST CTO-crossing catheter and the Pantheris LV image-guided atherectomy system.

Avinger, Inc.

Nasdaq:AVGR

AVGR Rankings

AVGR Stock Data

2.29M
2.93M
13.6%
2.84%
5.61%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
REDWOOD CITY